SIA
SPRY icon

Sit Investment Associates’s ARS Pharmaceuticals SPRY Stock Holding History

Sit Investment Associates’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$744K Hold
92,875
– – 0.01% 386
2026
Q1 		$746K Hold
92,875
– – 0.02% 386
2025
Q4 		$1.08M Buy
92,875
+18,350
+25% +$178K 0.02% 371
2025
Q3 		$749K Buy
74,525
+34,175
+85% +$490K 0.02% 388
2025
Q2 		$704K Buy
+40,350
New +$582K 0.02% 393

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Sit Investment Associates's SPRY Position: Q2 2026 in Review

Sit Investment Associates held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 92,875 shares worth $744K. The position accounts for 0.01% of the portfolio, ranked #386.

Sit Investment Associates first reported a position in SPRY in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.08M in Q4 2025. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Sit Investment Associates held 92,875 shares of ARS Pharmaceuticals worth $744K as of Q2 2026.
  • Sit Investment Associates left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up 0.01% of Sit Investment Associates's portfolio in Q2 2026, its #386 holding.
  • Sit Investment Associates first reported a position in ARS Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Sit Investment Associates's ARS Pharmaceuticals position peaked at $1.08M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Sit Investment Associates's 13F filing for Q2 2026, filed 12 Aug 2026.